351 related articles for article (PubMed ID: 35973745)
1. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy of locally/regionally advanced melanoma.
Khunger A; Buchwald ZS; Lowe M; Khan MK; Delman KA; Tarhini AA
Ther Adv Med Oncol; 2019; 11():1758835919866959. PubMed ID: 31391869
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad M; Tarhini AA
Curr Oncol Rep; 2023 Apr; 25(4):325-339. PubMed ID: 36781621
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.
Burton EM; Amaria RN; Cascone T; Chalabi M; Gross ND; Mittendorf EA; Scolyer RA; Sharma P; Ascierto PA
J Transl Med; 2022 Jun; 20(1):271. PubMed ID: 35706041
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
[TBL] [Abstract][Full Text] [Related]
10. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development.
Tarhini AA
Am Soc Clin Oncol Educ Book; 2015; ():e535-42. PubMed ID: 25993220
[TBL] [Abstract][Full Text] [Related]
13. Clinical updates in neoadjuvant immunotherapy for melanoma before surgery.
Saad M; Castellano E; Tarhini AA
Expert Rev Clin Immunol; 2023 Aug; ():1-17. PubMed ID: 37578289
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Conroy MR; Dennehy C; Forde PM
Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
[TBL] [Abstract][Full Text] [Related]
16. Preoperative therapy in melanoma: Evolving perspectives in clinical trials.
Kakish H; Xu K; Ahmed FA; Loftus AW; Elshami M; Hoehn RS; Ammori JB; Mangla A; Rothermel LD
Crit Rev Oncol Hematol; 2024 Jan; 193():104193. PubMed ID: 37926375
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
18. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
19. Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.
Ng G; Xu W; Atkinson V
Curr Oncol Rep; 2022 Oct; 24(10):1273-1280. PubMed ID: 35639333
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
Isaacs J; Stinchcombe TE
Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
